NCT04084704

A Prospective Evaluation of the Cingal Injection for Hip Osteoarthritis

A Prospective Evaluation of the Cingal Injection for Hip Osteoarthritis (ECHO Study)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: McMaster University · Academic / Other
• Sex: All
• Age: 40 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Osteoarthritis (OA) of the hip is one of the ten most disabling diseases in the developed world. Because OA gradually worsens over time, the sooner treatment is started, the more likely its impact is lessened. Hip OA is characterized by joint pain, cartilage degeneration, and an increase in disability. Multiple treatments are used to manage the degenerating hip as well as the associated pain. These include physiotherapy and rehabilitation, bracing, other walking aids, oral medications, injections, and in severe cases, surgery. Prior research has shown that injection of hyaluronic acid (HA) and corticosteroids can slow down OA degradation. This study will look at the effects of injecting Cingal into the hip, which expands on its current approved use in the treatment of knee OA.

Conditions

• Hip Osteoarthritis

Interventions

Type	Name	Description
DEVICE	Cingal	Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.

Timeline

• Start date: 2020-09-01
• Primary completion: 2023-06-07
• Completion: 2023-06-07
• First posted: 2019-09-10
• Last updated: 2023-09-21

Locations

1 site across 1 country: Canada